The Safety andImmunological Effects of Vaccine of rAd5-EBV-LMP2 in Nasopharyngeal Carcinoma Patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-12002502

Enrollment

Unknown

Registered

2012-09-11

Start date

2012-08-24

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharngeal Carcinoma

Interventions

1:Injection of rAd5-EBV-LMP2

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: advanced local disease (T3-T4, N0-N1, M0) or lymph node metastasis (T1-T2, N2-N3, M0); 2. Post-chemotherapy andradiotherapy 3 months, andnormal functions of liver, kidney andmarrow; 3. Positive IgA antibody to EBV-VCA; 4. Aged >=18; 5. Survival duration >=3 months; 6. Physical status score ECOG: 0-1; 7. Informed consents were signed from all patients prior to the study.

Exclusion criteria

Exclusion criteria: 1. Accompaniment by systemic infection, autoimmune disease or any immunodeficiency disease; 2. Pregnant or lactating women; 3. Treatment with systemic corticosteroid; 4. Allergy to drug; 5. HIV positive or active hepatitis B virus infection; 6. Other factors to unsuitable for the trials.

Design outcomes

Primary

Measure	Time frame
CTL;	—

Countries

China

Contacts

Public ContactZeng Yi

zengyicdc@sina.com+86 10 63544432

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026